<?xml version="1.0" encoding="UTF-8"?>
<p>Many pharmaceutical agents were tried empirically during the SARS epidemic in 2003. Savarino 
 <italic>et al.</italic> were the first to hypothesise the possible use of CQ in SARS,
 <sup>
  <xref rid="bibr25-2049936120947517" ref-type="bibr">25</xref>
 </sup> which led to further research by Keyaerts 
 <italic>et al.</italic> in 2004 at the Belgian Catholic University of Leuven on the 
 <italic>in vitro</italic> antiviral activity of CQ against SARS-CoV Frankfurt 1 strain.
 <sup>
  <xref rid="bibr26-2049936120947517" ref-type="bibr">26</xref>
 </sup> This study was conducted using Vero E6 cell culture, and there were promising results on inhibition of viral replication. Soon CQ became the preferred choice for prophylaxis and treatment of SARS due to its easy accessibility, administration, and low cost.
</p>
